Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2017 · 10-Q
Revenue$3.16M$3.16M+1.2% vs Q3 2016 Net Income-$2.20M-$2.20MN/M vs Q3 2016 EPS Diluted-$0.05-$0.05N/M vs Q3 2016 Gross Profit$421,539+20.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$678,031−21.8% Free Cash Flowderived$662,515−21.8% Margins · derivedGross margin13.3%+2.1 pt vs Q3 2016
Operating margin-65.0%−15.5 pt vs Q3 2016
Net margin-69.4%−13.4 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 14, 2017 · 45 d after period end